Renalyx Health Systems, has launched the RENALYX – RxT 21, the world’s first fully indigenous AI and cloud-enabled smart hemodialysis machine. This cutting-edge machine, which offers real-time remote monitoring and clinical connectivity, is priced starting at INR 6.70 lakh, significantly more affordable than imported dialysis machines. By making dialysis accessible at a lower cost, the RxT 21 will help bridge the gap in renal care, particularly in semi-urban and rural areas, where access to such services has traditionally been limited.
Completely designed and manufactured in India, the RENALYX – RxT 21 utilizes advanced technologies like cloud-based telenephrology platforms to provide safe, high-quality care for kidney patients, particularly those suffering from end-stage renal disease (ESRD), cardiovascular issues, pulmonary complications, or acute kidney injuries. With these innovations, the machine aims to improve the overall dialysis experience while reducing operational costs, making treatment more affordable for patients and healthcare providers.
It is the sixth company worldwide—and the first in India—to produce a dialysis machine that has received the EU CE certification, a significant milestone in the global medical device industry. This certification underscores the quality and safety standards of the RENALYX – RxT 21, positioning the company as a key player in the global renal care market. The company has also laid out plans to scale its production with a goal to manufacture 5,000 units by FY25-26 and an additional 1,500 machines by FY27-28.
In line with its ambitious growth strategy, the company plans to invest INR 800 crores over the next four years. The company intends to manufacture dialysis consumables locally and expand its production capacity across its facilities in Bengaluru, Mysuru, and Mumbai. Renalyx will also raise funds through equity sales, debt financing, and promoter investments. The company is also eyeing an IPO within the next three years, driven by strong interest from both domestic and international investors.
With plans to deploy the RxT 21 in Maharashtra and Karnataka initially, Renalyx aims to expand its distribution across India and internationally. The company has already secured orders from South Africa, the USA, and Europe. The machine’s advanced features include AI-based algorithms, cloud-integrated nephrology information systems, remote diagnostics, and continuous performance monitoring via IoMT (Internet of Medical Things). These capabilities allow doctors to remotely monitor patients and make necessary adjustments to their treatment in real-time, making dialysis services more efficient and accessible to a broader population. Renalyx also plans to deploy RxT 21 machines in primary health centers, community health centers, and private dialysis units across the country.
Additionally, Renalyx has partnered with Bharat Electronics Ltd. (BEL) to produce 6,000 units of the RENALYX – RxT 17, a previous model with standard features, over the next three years. By offering both the RxT 21 and RxT 17 models, Renalyx aims to make dialysis more affordable, especially in rural areas where healthcare resources are scarce. According to the Pradhan Mantri National Dialysis Program (PMNDP), India records around 2.2 lakh new cases of ESRD each year, contributing to a demand for over 3.4 crore dialysis sessions annually. Renalyx’s mission is to meet this growing demand by making dialysis treatment more accessible to the millions who need it.
Founded in 2012 and headquartered in Bengaluru, Renalyx Health Systems is committed to revolutionizing the field of renal care through technology and innovation. With a focus on addressing Chronic Kidney Disease (CKD), the company has developed a range of connected medical technologies, including its flagship product, the RENALYX – RxT 21. As an ISO 13485 certified medical device company, Renalyx prioritizes the highest standards of quality and safety. By making advanced renal care more affordable and accessible, Renalyx is transforming kidney care not just in India, but on a global scale.
